Remedy Robotics has raised $62 million in a Series B led by DCVC, adding the University of California’s investment office as a backer as it prepares trials across the university’s clinical network. The company says the money will support a planned pivotal study of its N1 robot and work toward FDA approval for neurovascular intervention.

N1 is designed to let physicians steer catheters through blood vessels, including from another hospital. The San Francisco company combines robotic controls with software that aligns three-dimensional scans with live X-ray images. Remedy says N1 remains investigational: its safety and effectiveness in clinical use are unproven, and it is unavailable for commercial sale.

Other new investors include Skip Capital and Australian pension fund Hostplus. The Series B exceeds the $35 million Remedy disclosed across its seed and Series A rounds in October 2025, according to DCVC’s account at the time.

An earlier remote milestone involved diagnostic imaging. In October 2025, DCVC said neurosurgeon Vitor Mendes Pereira had performed four cerebral angiograms with N1, including two from another Toronto hospital. The investor described remote removal of stroke-causing clots as a later goal.

Remedy also plans to place prototype N1 systems across its clinical partner network, including through SVIN Mission Thrombectomy and the Australian Stroke Alliance.

Sources
1Remedy Robotics Series B announcement ↗
2Remedy Robotics financing release — PR Newswire ↗
3Remedy Robotics technology and investigational status ↗
4DCVC’s October 2025 account of funding and remote procedures ↗